5 results
To assess PK of MPhs and MP.
The primary objective is to test the hypothesis that galcanezumab is superior to placebo in the prevention of migraine in patients with treatment-resistant migraine.The key secondary objective are:- To compare galcanezumab with placebo with respect…
Primary objectives- A multicenter, open label non-randomized phase I/II dose escalation study with extension cohort to determine the safety, tolerability and immunogenicity of the therapeutic LRPAP1 synthetic long peptide ( LRPAP7-30V-SLP) vaccine (…
PrimaryTo demonstrate the superiority of galcanezumab versus placebo in the prevention of migraine in an adolescent population (12 to 17 year-olds) with chronic migraineSecondary* To compare galcanezumab with placebo with respect to 50% response…
Main Objective:To demonstrate the superiority of galcanezumab versus placebo in the prevention of migraine in (at least) 1 of the following populations with migraine: the overall pediatric population (6 to 17 year-olds) or the adolescent population…